Micardis Plus

Micardis Plus Dosage/Direction for Use

telmisartan + hydrochlorothiazide

Manufacturer:

Boehringer Ingelheim
The information highlighted (if any) are the most recent updates for this brand.
Full Prescribing Info
Dosage/Direction for Use
Adults: MICARDIS PLUS should be taken once daily. The dose of telmisartan could be up-titrated before switching to MICARDIS PLUS. Direct change from monotherapy to the fixed combinations may be considered.
MICARDIS PLUS 40/12.5 mg may be administered in patients whose blood pressure is not adequately controlled by MICARDIS 40 mg or hydrochlorothiazide.
MICARDIS PLUS 80/12.5 mg may be administered in patients whose blood pressure is not adequately controlled by MICARDIS 80 mg or by MICARDIS PLUS 40/12.5 mg.
The maximum antihypertensive effect is generally attained with MICARDIS PLUS 4 - 8 weeks after the start of treatment. When necessary, MICARDIS PLUS may be administered with another antihypertensive drug.
Renal impairment: Due to the hydrochlorothiazide component, MICARDIS PLUS should not be used in patients with severe renal dysfunction (creatinine clearance < 30 mL/min). Loop diuretics are preferred to thiazides in this population. Experience in patients with mild to moderate renal impairment is modest but has not suggested adverse renal effects and dose adjustment is not considered necessary. Periodic monitoring of renal function is advised.
Hepatic impairment: In patients with mild to moderate hepatic impairment the posology should not exceed MICARDIS PLUS 40/12.5 mg once daily. MICARDIS PLUS is not indicated in patients with severe hepatic impairment. Thiazides should be used with caution in patients with impaired hepatic function.
Elderly: No dosage adjustment is necessary.
Children and adolescents: Safety and efficacy of MICARDIS PLUS have not been established in children and in adolescents up to 18 years.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in